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The clinical manifestations of Haemophilus influenzae infections and the growing problem of ampicillin-resistant strains are reviewed. Despite the fact that approximately 25 percent of H. influenzae are resistant to penicillin and ampicillin, oral aminopenicillins (ampicillin, amoxicillin, bacampicillin, and cyclacillin) are commonly used for the outpatient management of these infections. The characteristics of these drugs and the rationale for their use are discussed and compared with alternative approaches to therapy. This subject requires periodic review in consideration of the increasing prevalence of ampicillin and multiple antibiotic resistance among H. influenzae isolates.
H AENI0PHILUS IIVFLUENZAE (HI), pleomorphic gram-negative coccobacilli, are among the most common causes of bacterial infection in the pediatric age group. Six types are defined (a-f), on the basis of capsular antigens, type b accounting for most invasive disease. Infections of the tracheobronchial tract and its associated structures, however, are more commonly associated with nontypable (unencapsulated) strains. Moreover, all types can be pathogenic, as illustrated by a fatal case of fulminant septicemia with Waterhouse-Friderichsen syndrome in a 36-year-old man due to HI type f.' Sulfonamides, penicillin and, then, chloramphenicol all have been used to treat these infections. Traditional chemotherapy of HI infections more recently has consisted of ampicillin since its introduction in the 1960s. Other aminopenicillins, amoxicillin, cyclacillin, and bacampicillin are similarly active. This review examines the role of aminopenicillins in the ambulatory management of HI disease in the face of the increasing prevalence of betalactamase HI. Epidemiology HI infections occur throughout the year, but are most frequent in the winter and spring seasons. For example, a recent review of HI pneumonia documented that 80 percent of cases were seen between December and June.~ Invasive HI disease is most prevalent in children between the ages of 2 months to 5 years; however, infections have been documented in all age groups. Nontypable HI are normal upper respiratory tract flora in most infants and children, although less than 5 percent carry type b. Colonization with this virulent type is enhanced in contacts of symptomatic cases and may be associated with the presence of anticapsular antibody.3 Ampicillin-resistant HI, regardless of capsular structure, have been reported in carriers and infected patients worldwide. For example, recent reports document the presence of these organisms in Sweden,' New Zealand,s 5 France,' and England Host immunity to HI infections is not completely understood.' Anticapsular antibody has long been equated with bactericidal antibody and protection; however, opsonic antibody, complement, and other components of the immune system are also important.' Clinical Manifestations HI has been cultured from most sites in the body and can cause diverse clinical effects (Table 1 ). Of these, epiglottitis and meningitis are the most lethal, while otitis media is the most common. The actual contribution of HI to lower respiratory infections is poorly defined and probably underestimated because of the limitations of diagnostic techniques currently available. Development of antigen assay systems~ and other sensitive microbiological methods should provide a better estimate of the scope of this problem in the future. Ginsburg et al. recently reported that 83 percent of 65 children with HI pneumonia in Dallas were under 2 years of age.~ Interestingly, most of these consisted of consolidative lesions, and 75 percent also had pleural effusion. Moreover, otitis media was present in 43 percent, meningitis in 15 percent, and the infection was fatal in 5 percent of cases. 2 2 In approximately 20 to 30 percent of patients with otitis media, HI can be cultured from the middle ear. This is consistent with Schwartz's report that 29 percent of acute suppurative otitis media cases were due to HI.&dquo;
In general, HI I infections are insidious in onset and associated with prior viral upper respiratory infections. Rarely, fulminant septic shock may occur with rapidly fatal consequences. Although it is said that clinical features may suggest the etiologic diagnosis of HI cellulitis, bluish discoloration has been described in cellulitis due to other bacteria. Conversely, erysipelaslike cellulitis can be caused by HI. 12 2
Treatment of Hi Infections
Most patients with HI infections have otitis media, sinusitis, and other infections that do not require hospitalization and are treated with oral antibiotics. Since their introduction in the early 1960s, drugs of the ampicillin class quickly became the preferred treatment for HI infections. Rapid bactericidal activity, low toxicity, good patient tolerance, and impressive clinical results largely were responsible. Moreover, TABLE l. Cliniral Vlatzife,5tatioti.5 ty Haemophilus influen2ae Infectiolls clinicians could avoid the use of chloramphenicol with its potential for serious toxicities.
Although some ampicillin-resistant strains of HI have emerged in the past few years, many practitioners continue to prescribe oral ampicillins for the ambulatory management of common pediatric infections where HI are often the causative organisms (Table 2).
The use of ampicillins in otitis media may illustrate their rationale. Both Bluestonel3 and Klein' recommend that ampicillin-like drugs be used in the treatment of persistent middle ear effusion 13 and acute otitis media. 14 Klein summarized his reasons as follows:
Haemophilu5 litflue?izae is responsible for 20% of all episodes of otitis media; and in our area, 20% of strains of H. influenzae are resistant to ampicillin. Thus resistant strains represent 4% of all cases of otitis media. In addition, approximately one-third of all episodes of otitis media clear spontaneously, presumably by drainage of fluid via the eustachian tube or by perforation of the tympanic membrane. I am not ready to switch initial therapy on the basis of 2-3% incidence This opinion is reflective of the feelings of many practitioners and infectious disease subspecialists throughout the country. In fact, because the frequency of HI as the causative organism varies with the disease entity, the actual incidence of ampicillin resistance in a given disease may be quite low. If for example, the incidence of ampicillin-resistant HI is as high as 20 percent in a geographical area, in pneumonia (in which HI is the causative organism approximately 15% of the time) the rate of ampicillin resistance u7ould be only 3 percent (Table 3 ). The prevalence of beta-lactamase positive HI may continue to increase, however, and an increasing pathogenic role for other beta-lactamase producing bacteria, such as Branhamella crrtcrrrhalis, may require reassessment of this approach.
Oral Ampicillins
There are currently four oral aminopenicillins available in the United States: ampicillin, amoxicillin, bacampicillin, and cyclacillin (Table 4 ). Several characteristics of each drug are distinguishing, although they are all expected to be active in the treatment of beta-lactamase negative HI infections. Patients allergic to penicillin are also allergic to all the aminopenicillins.
Ampicillin is the least well absorbed of these drugs by the oral route and, if degree of drug absorption in the upper GI tract is important in the pathogenesis of diarrhea, may be more likely to cause this side effect. In fact, the incidence of ampicillin-related diarrhea has been reported to be as high as 22 percent. Rashes are seen with all these products in approximately 1 to 4 percent of cases.
Although clinical experience is greatest with ampicillin, the other oral aminopenicillins have largely supplanted its use because of their superior absorption after oral administration. Amoxicillin arrived on the scene several years before bacampicillin and cyclacillin, and there is considerable clinical experience with its oral use in the treatment of HI infections. Amoxicillin should not be used for the treatment of shigellosis because of clinical failures (attributed to interference of human serum with antishigella activity of amoxicillin).'&dquo;
Bacampicillin is a pro-drug of ampicillin that is well absorbed after oral administration. It Cyclacillin also is absorbed rapidly after oral administration. In fact, peak serum concentrations are three to four times those achieved with ampicillin.'s This advantage is somewhat offset by the fact that the drug is 25 to 60 percent less active in vitro than ampicillin or amoxicillin against HI and other common respiratory bacterial pathogens.26
Other Antimicrobials
There are several oral drugs that could be used as alternatives to ampicillins in infections due to ampicillin-resistant HI or in patients truly allergic to penicillin or, rarely, in those with marked adverse reactions to aminopenicillins. These include trimethoprim-sulfamethoxazole, cefaclor, erythromycin plus a sulfonamide, cefaclor plus a sulfonamide, 21 or chloramphenicol. There are some limitations, however, to these approaches. Occasionally, strains of HI are tolerant (tolerance refers to bacteria that are , killed only by concentrations 32-fold or greater than that required for inhibition) to trimethoprim-sulfamethoxazole 28 and are less effectively treated because of this characteristic. Moreover, this combination is less active in vitro against large inocula of His Cefaclor is less consistently active against beta-lactamase negative HI than ampicillins, and penetrates poorly into the central nervous system. Combinations of cefaelcar or erythromycin with sulfonamides are largely untested clinically but hold less appeal than ampicillins because of the likelihood of increased toxicities, bacteriostatic activity, and added expense. Chloramphenicol would be the best candidate for the oral therapy of HI infections because of its excellent pharmacokinetic and potent antimicrobial properties.&dquo; The major limitations of this approach are the drug's hematologic toxicities and the emergence of HI resistant to chloramphenicol. Although the prevalence of chloramphenicol-resistant HI remains low « 1 %) in North America,&dquo;'~~ it is increasing in some countries, such as Spain, where 16 strains resistant to ampicillin and chloramphenicol were recovered recently from children with serious invasive infections over a 22-month period.31 Moreover, the genetic mechanisms (R-plasmids) for rapid spread of chloramphenicol-resistance favor an increase in the prevalence of these strains worldwide. 30 Despite these limitations, chloramphenicol is preferred for oral therapy of serious invasive HI infections, such as meningitis, bone and joint infections, mastoiditis, and ventricular shunt infections.
Combinations of ampicillins with beta-lactamase inhibitors, such as clavulanic acid, may be a useful alternative in the future .32 The basis for this combination is the inhibition of beta-lactamase by clavulanic acid, a product of Streptomyres rlavuligerus with pharmacokinetic properties similar to amoxicillin,.33 Clavulanic acid, however, has only weak antibacterial activity and would not be expected to enhance aminopenicillin action against resistance mediated by nonbeta-lactamase mechanisms. Clinical trials have shown efficacy in a variety of infections, but gastrointestinal side effects (diarrhea, nausea, vomiting) have been more frequent than with comparison drugs in both children&dquo;' and adults.35 Most importantly, use of drugs other than aminopenicillins should be based on documented rates of HI ampicillin resistance in particular geographic areas, as well as clinical failure rates in diseases due to these bacteria.
Haemophilus influenzae Resistant to Antibiotics
HI may be resistant to a variety of antibiotics ( Table 5 ). The mechanisms and genetics of HI resistance to parenteral antibiotics have been reviewed recently.30 The term &dquo;resistance&dquo; is a relative one and may be variably defined, depending on methodologies used&dquo; and the site of infection. For example, ampicillin resistance in cases with meningitis is defined as HI requiring more than 2 Ag/ml for inhibition, whereas 8 pg/ml often is used as the cutoff point when infections outside of the central nervous system are considered. This is because of the erratic penetration of ampicillin into cerebrospinal fluid. Ampi- issued a statement about these observations41.42; however, the true incidence of resistant strains was unknown at that time. A nationwide survey of laboratory physicians was carried out from 1975 through 1976 and showed an incidence of HI ampicillin resistance of 3 to 9 percent in the United States.4s Since the mechanism apparently was due to plasmid-mediated beta-lactamase production,H-46 it was expected that the spread of resistance might be fairly rapid and that this would markedly limit the use of ampicillin in HI infections in subsequent years. Indeed, the frequency of ampicillin-resistant HI has increased dramatically in some geographic areas in the country.47 It must be remembered, however, that the incidence of ampicillin resistance is subject to many influences: selection of the study population, since prior exposure to antibiotics may enhance the isolation of ampicillin-resistant organisms37.48; susceptibility methods, since disc diffusion may overestimate resistance if the inoculum is too heavy'9,50 ; and frequency of ampicillin-resistant HI in patients with relapsing otitis media and in certain geographic areas. Sometimes, both resistant and sensitive HI are present in the same patient. 51, 52 As stated, the incidence of ampicillin-resistant HI has increased in some centers. For example, 1.6 percent of isolates in Houston were resistant in 1974;
whereas, the figure rose to 14.3 percent in 1978. 53
In a similar survey of HI from Huntsville and Boston, the incidence was 1.5 to Some repqrts are more encouraging. For example, 8 percent of 79 middle ear HI isolates in Pittsburgh in a study from 1978 to 1980 were resistant to ampicillin.'7 The incidence of resistance, however, dropped from 14 percent in 1979 to 4 percent in 1980. In many other regions of the country, the incidence has remained stable at low percentages.
The recent description of strains of HI resistant to both ampicillin and chloramphenicol are disconcerting, since, in many cases, the mechanism is plasmidmediated beta-lactamase and acetyltransferase.57,58 So far, however, the early reports59-61 have not been followed by frequent experience with this type of organism.
Summary
There are several well-absorbed and effective oral aminopenicillins that can be used for the treatment of susceptible HI infections. Because of the frequency of the infections and the favorable properties of these drugs, practitioners have come to rely upon them as first-line therapies for many infections due to HI. The development of ampicillin resistance has emphasized the need for careful follow-up of such patients in anticipation of clinical failures and their early diagnosis. Most practitioners prefer to use this approach, rather than alternate drug regimens, for the vast majority of children suffering from respiratory HI infections. Future strategies will depend on continued surveillance of the scope of the problem of ampicillin resistance among HI isolates, clinical failure rates, new drug development, and methods to improve the presently available ampicillin formulations.
